Who is searching for your site?
- Patients: 22% of participants learned about their trial online (CISCRP via Citeline).
- Physicians checking a site before referring.
- Sponsors and CROs looking for sites; sites at SCRS were told to keep websites current with investigator credentials and studies (Bourne Partners).
What pages should a site have?
- One page per active study: condition, what is involved, location, and contact.
- One page per therapeutic area: the conditions you research, your investigators, and past experience.
- An investigators page with credentials.
- A sponsor page: capabilities, therapeutic areas, and metrics.
- A referring physicians page: how to refer, and what you send back.
What needs IRB review?
FDA guidance says basic trial listings, limited to information such as title, purpose, protocol summary, basic eligibility criteria, location, and contact information, do not require IRB review. Anything beyond that, such as descriptions of benefits or persuasive content, is recruitment material the IRB should review (FDA). Confirm your IRB's policy.
How do AI assistants change this?
People now ask ChatGPT and other assistants for recommendations, and those tools draw on clear, factual web pages. TrialNotice itself has won a client who found it through ChatGPT. Pages that answer specific questions plainly, with real numbers and sources, are the ones AI tools cite.
What should you measure?
- Inquiries per study page, by source.
- Prescreener completion rate.
- Screens and randomizations from web inquiries.
Where does SEO stop?
SEO captures people already looking. Only 10% of people who never participated were ever asked (CISCRP); most eligible patients are not searching. Their doctors are the ones who can bring the study to them, which is why a findable website and a physician referral program work best together.
Get your study in front of the right local physicians
TrialNotice builds a physician referral pipeline around one active study. We identify relevant local physicians within driving distance of your site, send study aligned direct mail, follow up by email and LinkedIn, track engagement with recipient level QR codes, and route warm responses into your site team's workflow.
Talk to TrialNoticeSources
- FDA, "Recruiting Study Subjects" guidance for IRBs and clinical investigators
- Citeline, Patient Recruitment Pulse (Jan 2026) on the CISCRP 2025 Perceptions and Insights Study
- CISCRP, 2017 Perceptions and Insights Study: Decision Making Process
- Bourne Partners, "Update on the Fundamentals of Clinical Trial Sites" (SCRS Global Site Solutions Summit takeaways, October 2025)